Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Mivebresib
Synonyms
Therapy Description

ABBV-075 (Mivebresib) is a bromodomain (BET) inhibitor, which may inhibit Ar and Myc downstream signalling to prevent growth and proliferation of tumor cells (PMID: 30647404).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Mivebresib ABBV-075 BET Inhibitor (Pan) 30 Mivebresib (ABBV-075) is a bromodomain (BET) inhibitor, which may disrupt transcriptional regulation and lead to apaotosis of tumor cells (PMID: 28416490, PMID: 31420359).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown acute myeloid leukemia not applicable Mivebresib Preclinical - Patient cell culture Actionable In a preclinical study, Mivebresib (ABBV-075) induced apoptosis and inhibited growth of acute myeloid leukemia (AML) cell lines and patient-derived cells in culture, and inhibited tumor growth in an AML cell line xenograft model (PMID: 28416490). 28416490
Unknown unknown multiple myeloma not applicable Mivebresib Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with Mivebresib (ABBV-075) altered expression of ZCCHC24, HEXIM1, SERPINI1, and MYC in a multiple myeloma cell line in culture and in xenograft models, and these changes correlated with inhibition of proliferation in culture and inhibition of tumor growth in xenograft models (PMID: 27903752). 27903752
Unknown unknown Advanced Solid Tumor not applicable Mivebresib Phase I Actionable In a Phase I trial, Mivebresib (ABBV-075) treatment demonstrated safety and modest clinical activity, resulted in stable disease as best response in 43% (26/61) of evaluable patients with advanced solid tumors, with a median progression-free survival of 1.8 months (PMID: 31420359; NCT02391480) . 31420359
Unknown unknown uveal melanoma not applicable Mivebresib Phase I Actionable In a Phase I trial, Mivebresib (ABBV-075) treatment demonstrated safety and modest clinical activity in patients with uveal melanoma, resulting in stable disease as best response in 44% (4/9) of evaluable patients, patients achieved stable disease had lower cfDNA mutational load of pathogenic mutations (53.1 vs 893.9 median mutant molecules/mL plasma) compared to patients developed progressive disease (J Clin Oncol 37, no. 15_suppl; NCT02391480). detail...

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04480086 Phase I Mivebresib + Navitoclax Mivebresib + Ruxolitinib Mivebresib Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis Recruiting USA 11
NCT02391480 Phase I Mivebresib A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer Completed USA 0


Additional content available in CKB BOOST